Over the past decade, Novartis Pharmaceuticals Canada has introduced 20 new medicines that have had an important impact on patients suffering from a wide variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation and osteoporosis.
Novartis is one of the industry’s biggest investors in research.
This information is intended for Canadian healthcare professionals only
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis
Sandoz is one of the leaders in the development, manufacturing and distribution of generic pharmaceutical products.